GBT Announces New Employment Inducement Grants
09 déc. 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on December 1, 2021, the compensation committee of GBT’s board...
GBT Supports the ASH Research Collaborative’s Data Hub Sickle Cell Disease Program
02 déc. 2021 08h00 HE
|
Global Blood Therapeutics, Inc.; The ASH Research Collaborative
WASHINGTON and SOUTH SAN FRANCISCO, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- The ASH Research Collaborative (ASH RC), a non-profit organization established in 2018 by the American Society of...
GBT Announces Participation at the 4th Annual Evercore ISI HealthCONx Conference
24 nov. 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the 4th...
GBT Announces Participation in Upcoming Investor Conferences
12 nov. 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Stifel...
GBT Announces New Employment Inducement Grants
08 nov. 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on November 1, 2021, the compensation committee of GBT’s board...
GBT Reports Third Quarter 2021 Financial Results
04 nov. 2021 16h05 HE
|
Global Blood Therapeutics, Inc.
Achieved Oxbryta® (voxelotor) net revenues of $52.1 million, a 41% increase year over year Oxbryta sNDA and NDA for pediatric label expansion accepted by FDA for priority review; PDUFA target...
GBT Announces Six Data Presentations on Sickle Cell Disease at Upcoming 63rd American Society of Hematology (ASH) Annual Meeting & Exposition
04 nov. 2021 09h05 HE
|
Global Blood Therapeutics, Inc.
Accepted Abstracts Include Real-World Experience with Oxbryta® (voxelotor) and Phase 1 Data on GBT021601 and Inclacumab SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Global Blood...
GBT Wins Prestigious Prix Galien USA Award for Oxbryta® (voxelotor)
01 nov. 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
Considered the equivalent of the Nobel Prize in biopharmaceutical research, Prix Galien USA honors Oxbryta as the Best Biotechnology Product for 2021 Oxbryta is the first and only approved therapy...
GBT to Announce Third Quarter 2021 Financial Results on Thursday, November 4
28 oct. 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
Company to also host R&D Day on Thursday, November 11 in New York City and via video webcast SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT)...
GBT Announces New Employment Inducement Grants
07 oct. 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on October 1, 2021, the compensation committee of GBT’s board...